Luis Pierpauli
CEO

The startup has developed a nanotechnology-based device for the real-time diagnosis and detection of renal biomarkers, enabling the measurement of urea, creatinine, and potassium levels from a single drop of blood. This portable platform allows scientists to monitor kidney health efficiently through a dedicated application, facilitating timely interventions in renal care.
Raised to date
$220KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Traditional methods for monitoring kidney function often require laboratory equipment, trained personnel, and can be time-consuming, hindering frequent and convenient testing. Current diagnostic approaches may also require large sample volumes and lack the ability to provide real-time results.
Gisens Biotech offers a nanotechnology-based point-of-care diagnostic platform for real-time monitoring of renal biomarkers. Their portable device, about the size of a smartphone, measures urea, creatinine, and potassium levels from a single drop of blood, urine, or saliva. The device incorporates highly sensitive biosensors that do not require chemical reagents or calibration. Results are transmitted via Bluetooth to a dedicated application on a smartphone, tablet, or computer, enabling easy access, sharing, and long-term data storage. Healthcare professionals can utilize a dedicated app with comprehensive reports for real-time patient follow-up.
The primary target audience includes patients with kidney conditions requiring frequent monitoring, healthcare providers in nephrology and primary care, and clinical researchers focused on renal disease.